Group One Trading’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.93M | Buy |
113,828
+23,779
| +26% | +$333K | ﹤0.01% | 2253 |
|
|
2026
Q1 | $1.15M | Sell |
90,049
-636
| -0.7% | -$8.1K | ﹤0.01% | 2577 |
|
|
2025
Q4 | $815K | Sell |
90,685
-6,400
| -7% | -$88.1K | ﹤0.01% | 3084 |
|
|
2025
Q3 | $1.68M | Sell |
97,085
-64,151
| -40% | -$790K | ﹤0.01% | 2496 |
|
|
2025
Q2 | $1.51M | Buy |
161,236
+144,235
| +848% | +$1.18M | ﹤0.01% | 2392 |
|
|
2025
Q1 | $121K | Sell |
17,001
-30,241
| -64% | -$305K | ﹤0.01% | 4452 |
|
|
2024
Q4 | $551K | Buy |
47,242
+38,437
| +437% | +$600K | ﹤0.01% | 3092 |
|
|
2024
Q3 | $181K | Buy |
8,805
+174
| +2% | +$4.01K | ﹤0.01% | 3709 |
|
|
2024
Q2 | $193K | Buy |
+8,631
| New | +$206K | ﹤0.01% | 3422 |
|
|
2024
Q1 | – | Sell |
-11,480
| Closed | -$319K | – | 7690 |
|
|
2023
Q4 | $350K | Buy |
11,480
+6,825
| +147% | +$196K | ﹤0.01% | 3370 |
|
|
2023
Q3 | $147K | Sell |
4,655
-4,751
| -51% | -$184K | ﹤0.01% | 4076 |
|
|
2023
Q2 | $384K | Buy |
+9,406
| New | +$381K | ﹤0.01% | 3285 |
|
|
2023
Q1 | – | Sell |
-13,168
| Closed | -$516K | – | 7701 |
|
|
2022
Q4 | $459K | Buy |
+13,168
| New | +$626K | ﹤0.01% | 3120 |
|
|
2022
Q3 | – | Sell |
-26,901
| Closed | -$1.67M | – | 8013 |
|
|
2022
Q2 | $1.39M | Buy |
+26,901
| New | +$1.37M | ﹤0.01% | 2405 |
|
|
2021
Q3 | – | Sell |
-28,210
| Closed | -$4.27M | – | 8585 |
|
|
2021
Q2 | $4.57M | Buy |
28,210
+12,423
| +79% | +$967K | 0.01% | 1780 |
|
|
2021
Q1 | $1.27M | Buy |
15,787
+9,612
| +156% | +$645K | ﹤0.01% | 2955 |
|
|
2020
Q4 | $336K | Buy |
+6,175
| New | +$224K | ﹤0.01% | 3630 |
|
|
2020
Q2 | – | Sell |
-11,845
| Closed | -$201K | – | 6050 |
|
|
2020
Q1 | $145K | Buy |
11,845
+2,391
| +25% | +$32.2K | ﹤0.01% | 3000 |
|
|
2019
Q4 | $139K | Sell |
9,454
-1,949
| -17% | -$27.1K | ﹤0.01% | 3431 |
|
|
2019
Q3 | $152K | Buy |
11,403
+10,264
| +901% | +$164K | ﹤0.01% | 3273 |
|
|
2019
Q2 | $19K | Sell |
1,139
-5,400
| -83% | -$84.9K | ﹤0.01% | 4196 |
|
|
2019
Q1 | $112K | Buy |
6,539
+800
| +14% | +$11.9K | ﹤0.01% | 3096 |
|
|
2018
Q4 | $78K | Buy |
5,739
+3,453
| +151% | +$64.2K | ﹤0.01% | 3318 |
|
|
2018
Q3 | $65K | Sell |
2,286
-9,888
| -81% | -$288K | ﹤0.01% | 3813 |
|
|
2018
Q2 | $333K | Sell |
12,174
-73,916
| -86% | -$1.79M | ﹤0.01% | 2636 |
|
|
2018
Q1 | $1.82M | Buy |
86,090
+47,223
| +121% | +$1.16M | 0.02% | 1072 |
|
|
2017
Q4 | $747K | Buy |
38,867
+31,262
| +411% | +$722K | 0.01% | 1935 |
|
|
2017
Q3 | $189K | Sell |
7,605
-5,767
| -43% | -$109K | ﹤0.01% | 2800 |
|
|
2017
Q2 | $214K | Buy |
13,372
+4,672
| +54% | +$65.3K | ﹤0.01% | 2596 |
|
|
2017
Q1 | $123K | Buy |
+8,700
| New | +$117K | ﹤0.01% | 2837 |
|
Other funds holding NTLA
AIM
RCM
RP
Group One Trading's NTLA Position: Q2 2026 in Review
Group One Trading increased its Intellia Therapeutics (NTLA) stake by 26% in Q2 2026, buying an estimated $333K and bringing the position to 113,828 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2253.
Group One Trading first reported a position in NTLA in Q1 2017 and has held it in 30 quarters since. The position peaked at $4.57M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Group One Trading held 113,828 shares of Intellia Therapeutics worth $1.93M as of Q2 2026.
- Group One Trading bought 23,779 Intellia Therapeutics shares in Q2 2026, an estimated $333K.
- Intellia Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #2253 holding.
- Group One Trading first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 30 quarters since.
- Group One Trading's Intellia Therapeutics position peaked at $4.57M in Q2 2021.
- 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.